TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01177137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional sound generator (SG)
Description: Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo sound generator (placebo SG)
Description: Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care (SC)
Description: The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directive Counseling (DC)
Description: Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directive Counseling (DC)
Description: Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
Study: NCT04097691

Intervention type: DRUG
Intervention: GLUCOSE 10%
Description: subcutaneous glucose 0.5 ml per site around subcutaneous nerves

Intervention type: DRUG
Intervention: GLUCOSE 10%
Description: subcutaneous glucose 0.5 ml per site around subcutaneous nerves
Study: NCT04047225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE ANALGESIA NOCICEPTIVE INDEX (ANI)
Description: Utilisation of the ANI during the operation
Study: NCT01816100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specifically design 6 month resistance training program
Description: Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 months weight resistance and balance program
Description: 3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
Study: NCT04059393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02049060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: •- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
Study: NCT01093222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT04051190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLED group
Description: 10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLED group
Description: 10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLED group
Description: 10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy group
Description: Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
Study: NCT03053921

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: recession coverage
Description: recession coverage done using Zuchellis technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recession coverage and membrane
Description: recession coverage done using Zuchellis technique with placental membrane
Study: NCT01703702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir (18F)
Description: Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Study: NCT02362776

Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood

Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood
Study: NCT01726387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Counseling
Description: Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Depending on the conditions, patients get usual care of their general practitioner
Study: NCT00814944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 440 micrograms sirolimus in each eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 220 micrograms sirolimus in each eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subconjunctival injection of 880 micrograms sirolimus in each eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus
Description: Subconjunctival injection of placebo in each eye.
Study: NCT04519788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-301B
Description: Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT-301A
Description: Nasal Spray
Study: NCT01825356

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation
Study: NCT03054064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Exoskeleton
Description: Six study sessions including five Indego training sessions over two weeks.
Study: NCT01844505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Ipilimumab
Study: NCT03260517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Coronary Drug-Coated Balloon Catheter
Description: Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
Study: NCT01945801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasilactone
Description: Active drug (spironolactone 100 mg plus furosemide 20 mg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-Restricted Diet
Description: The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
Study: NCT02864927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular. 2 doses 3 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03584464

Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
Study: NCT04036305

Intervention type: DRUG
Intervention: 0.9% Sodium Chloride Injection
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Intervention: 0.9% Sodium Chloride Injection
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Intervention: Lidocaine Injection 2%
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Intervention: Lidocaine Injection 2%
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Intervention: Bupivacaine Injection 0.5%
Description: All participants will be injected subcutaneously with a single 0.5ml dose

Intervention type: DRUG
Intervention: Bupivacaine Injection 0.5%
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study: NCT01041976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Motivational Interviewing (AMI)
Description: Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support and Education for Recovery (SER)
Description: Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
Study: NCT03998163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg administered three times/week
Study: NCT04051190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass group
Description: Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
Study: NCT02949622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program
Description: The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)
Study: NCT03118375

Intervention type: DEVICE
Intervention: super-power BAHA processor
Description: The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
Study: NCT04191070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrazygomatic miniscrew
Description: class II correction by distalization using infrazygomatic crest miniscrew
Study: NCT02949622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
Study: NCT03512587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized quantum sonotherapy
Description: Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Headphones will be place in patients without playing quantum sonotherapy
Study: NCT03578419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small-Volume Blood Collection Tubes
Description: Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Volume Blood Collection Tubes
Description: Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
Study: NCT04191070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zygomatic miniplate
Description: class II correction by distalization using zygomatic miniplate
Study: NCT04152785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.
Study: NCT01670188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic SCD - VenaFlow System (DJO Global)
Study: NCT00836914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL-101
Description: CAL-101 100mg capsules administered orally twice a day (BID) for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally BID for 7 days
Study: NCT06210737

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 2 doses of PCV13, and a booster dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 2 doses of PCV13

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: single dose of PCV13
Study: NCT04152785

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.
Study: NCT04544228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block Technique
Description: The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block Technique
Description: The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block Technique
Description: The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
Study: NCT02702739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
Description: Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
Description: Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
Study: NCT02896439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurophysiological MONITORING
Description: The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention
Study: NCT03942783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WORKWELL
Description: Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
Study: NCT04544228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes.
Study: NCT02775877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole